Company Overview and News
Tyre maker Goodyear India is evaluating to enter various segments, including commercial vehicles tyres, as part of plans to expand operations in the country, a top company official said today.
Market Update: The market held on to morning gains, with the Sensex rising around 150 points while the Nifty Midcap index extended rally, rising nearly 1.5 percent.
519588 PWQFY PANAMAPET 500325 BHUSANSTL UBL 532439 TCHQY ASIANPAINT 532321 PIDILITIND PDLTY 500850 BJJQY MS 500570 524820 500055 500331 JMFINANCIL SNDMY RLNIY GE 534690 515030 532827 UNITDSPR 531978 JETAIRWAYS 532945 YYBKY 530005 532432 BAJAJFINSV VED 500180 COALINDIA GOLDINFRA 500820 GOODYEAR IDBI PNCINFRA 514034 532899 532810 TTNQY 533477 532540 ZUARIGLOB 512529 RIGD INFRATEL INDHOTEL TATAMOTORS 500034 514043 SUNDARMFIN INDUSINDBK UBHOLDINGS 513599 532527 532648 UNBWY VTUWY CDLYY OBEROIRLTY HDB 500168 GNE KARURVYSYA EXCELINDUS TTM 523405 RICOAUTO 539150 PAGEIND 590003 HIMATSEIDE RKFORGE 532755 532478 532511 CADILAHC 532482 534816 JBFIND KSCL 500378 500252 CLNDY 500650 PGDQY ENKEIWHEL 520008 AMBIKCO 539302 LAXMIMACH TECHM BAJFINANCE TATASTEEL TATLY JINDALSAW UQNTY TCS 534809 PCJEWELLER 507458 500780 WABAG HINDCOPPER SHRIRAMEPC BHRYY MONTECARLO RELIANCE ASAHIINDIA 532617 533273 532978 533278 538836 GRANULES 500470 532187 HDFCBANK SEQUENT INDIACEM 590071 YESBANK GEC 500116 533269 POWERMECH PFC DFM OBZIY TTST LAKSHVILAS EXCELCROP
2018-08-13 - Asif
Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...
2018-08-13 - Asif
Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...
2018-08-13 - Asif
Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...